0000059478-22-000277.txt : 20221213 0000059478-22-000277.hdr.sgml : 20221213 20221213070351 ACCESSION NUMBER: 0000059478-22-000277 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221213 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20221213 DATE AS OF CHANGE: 20221213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 221458529 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 8-K 1 lly-20221213.htm 8-K lly-20221213
0000059478false00000594782022-12-132022-12-130000059478us-gaap:CommonClassAMember2022-12-132022-12-130000059478lly:A718NotesDueJune12025Member2022-12-132022-12-130000059478lly:A1.625NotesDueJune22026Member2022-12-132022-12-130000059478lly:A2.125NotesDueJune32030Member2022-12-132022-12-130000059478lly:A625Notesdue2031Member2022-12-132022-12-130000059478lly:A500NotesDue2033Member2022-12-132022-12-130000059478lly:A6.77NotesDueJanuary12036Member2022-12-132022-12-130000059478lly:A1625NotesDue2043Member2022-12-132022-12-130000059478lly:A1.700Notesdue2049Member2022-12-132022-12-130000059478lly:A1125NotesDue2051Member2022-12-132022-12-130000059478lly:A1375NotesDue2061Member2022-12-132022-12-13

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 13, 2022
ELI LILLY AND COMPANY
(Exact Name of Registrant as Specified in its Charter) 
Indiana 001-06351 35-0470950
(State or Other Jurisdiction
of Incorporation)		 (Commission
File Number)		 (I.R.S. Employer
Identification No.)
  


Lilly Corporate Center
Indianapolis,Indiana46285
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (317) 276-2000

Not Applicable
(Former Name or Former Address, if Changed Since Last Report.) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock (no par value)LLYNew York Stock Exchange
7 1/8% Notes due 2025LLY25New York Stock Exchange
1.625% Notes due 2026LLY26New York Stock Exchange
2.125% Notes due 2030LLY30New York Stock Exchange
0.625% Notes due 2031LLY31New York Stock Exchange
0.500% Notes due 2033LLY33New York Stock Exchange
6.77% Notes due 2036LLY36New York Stock Exchange
1.625% Notes due 2043LLY43New York Stock Exchange
1.700% Notes due 2049LLY49ANew York Stock Exchange
1.125% Notes due 2051LLY51New York Stock Exchange
1.375% Notes due 2061LLY61New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 2.02. Results of Operations and Financial Condition.

On December 13, 2022, Eli Lilly and Company (the “Company”) issued a press release announcing its financial guidance for 2023. In addition, on the same day, the Company held a teleconference for analysts and media to discuss this guidance. The teleconference was webcast on the Company’s website. The press release is attached to this Form 8-K as Exhibit 99.1.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.








Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document).













































SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELI LILLY AND COMPANY
(Registrant)
By:/s/ Donald A. Zakrowski
Name:Donald A. Zakrowski
Title:Senior Vice President, Finance, and
Chief Accounting Officer
Date: December 13, 2022

 EX-99 2 lly-2023financialguidancep.htm EX-99 Document
logoa31a.jpg



Dec. 13, 2022




For Release:    Immediately
Refer to:    Jordan Bishop; jordan.bishop@lilly.com; (317) 473-5712 (Media)
Joe Fletcher; jfletcher@lilly.com; (317) 296-2884 (Investors)

Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines

•Lilly expects to deliver strong financial and operational performance in 2023, highlighted by volume-driven revenue growth; potential launches for donanemab, mirikizumab, lebrikizumab and pirtobrutinib; potential regulatory submissions for tirzepatide in obesity; and numerous other anticipated pipeline advancements.
•Continued pipeline progress in 2023 includes expected initiation of Phase 3 clinical trials for retatrutide (GGG tri-agonist) in obesity and orforglipron (oral GLP-1 NPA) in type 2 diabetes and obesity, and key Phase 3 readouts, which include donanemab for early Alzheimer's disease and mirikizumab for Crohn's disease.
•2023 revenue expected to be between $30.3 billion and $30.8 billion, driven by key growth products.
•2023 EPS expected to be in the range of $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis.
•The company reaffirmed its 2022 financial guidance on both a reported and non-GAAP basis.
•Fifth consecutive 15% annual increase in dividend for 2023, doubling since 2018 and underscoring increasing confidence in the company's outlook.

INDIANAPOLIS, Dec. 13, 2022 -- Eli Lilly and Company (NYSE: LLY) today announced its 2023 financial guidance, highlighted by expected volume-based revenue growth and increased investments to maximize future value. The company will review potential key events for the upcoming year, including important data readouts for several investigational medicines in its clinical pipeline and the possibility of multiple regulatory submissions and approvals, in a call with investors today.

"Lilly is exiting 2022 with momentum. Our approved and available medicines are early in their life cycles and showed accelerated growth during the year, led by a strong Mounjaro launch. In addition, several of our late-stage medicines for serious diseases were submitted for approval this year, and will hopefully launch in 2023," said David A. Ricks, Lilly's chair and CEO. "We continue to innovate and are beginning new pivotal studies for the next group of potential breakthrough treatments. In
Eli Lilly and Company | Lilly Corporate Center | Indianapolis, Indiana 46285 | U.S.A.




the decade ahead, we are well-positioned to create significant value for patients with challenging conditions, health systems struggling to manage chronic disease, and of course, our shareholders."

Anat Ashkenazi, Lilly's executive vice president and chief financial officer, outlined the company's expectations for its growth prospects: "We believe we have the potential to deliver top-tier, volume-driven revenue growth through at least 2030 with groundbreaking medicines. In addition to the tremendous on-going launch of Mounjaro in type 2 diabetes and expected future opportunities to treat obesity and obesity-related metabolic outcomes with tirzepatide, we plan to invest in our four significant potential new launches next year. With limited patent expirations this decade, we believe these potential new medicines and the continued scaling of our key growth products will fuel our next wave of growth. Lilly is committed to maximizing long-term value for stakeholders and we look forward to delivering further in 2023."

2022 Financial Guidance
The company reaffirmed its 2022 financial guidance on both a reported and non-GAAP basis. The company's 2022 financial guidance reflects adjustments shown in the reconciliation table below.
2022
Expectations		% Change vs 2021
Earnings per share (reported)$6.50 to $6.656% to 9%
Net losses on investments in equity securities(1)
.52
Amortization of intangible assets.51
Asset impairment, restructuring, and other special charges.17
Earnings per share (non-GAAP)$7.70 to $7.854% to 6%
Numbers may not add due to rounding
Acquired IPR&D and development milestone charges(2)
$.67
(1) The company's guidance does not reflect the impact of net gains or losses on investments in equity securities during Q4 2022.
(2) The company's guidance does not include any acquired IPR&D or development milestone charges incurred during Q4 2022.



 2





The company reaffirmed its 2022 financial guidance, as set forth in the following table:
2022 Guidance
Revenue$28.5 to $29.0 billion
Gross Margin % of Revenue (reported)Approx. 76%
Gross Margin % of Revenue (non-GAAP)Approx. 78%
Marketing, Selling & Administrative$6.4 to $6.6 billion
Research & Development$7.1 to $7.3 billion
Acquired IPR&D & Development Milestones
Approx. $670 million
Other Income/(Expense) (reported)$(700) to $(600) million
Other Income/(Expense) (non-GAAP)$(100) million to $0
Tax RateApprox. 13% to 14%
Earnings per Share (reported)$6.50 to $6.65
Earnings per Share (non-GAAP)$7.70 to $7.85
Operating Margin % (reported)Approx. 26%
Operating Margin % (non-GAAP)Approx. 29%
Non-GAAP guidance reflects adjustments presented in the earnings per share table above.

2023 Financial Guidance
Earnings per share (EPS) for 2023 is expected to be in the range of $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis. The company's 2023 financial guidance reflects the adjustment shown in the reconciliation table below.


 3





2023
Expectations
Earnings per share (reported)$7.65 to $7.85
Amortization of intangible assets.45
Earnings per share (non-GAAP)$8.10 to $8.30
Numbers may not add due to rounding.
The company's 2023 financial guidance does not include any impact from potential or pending business development transactions or potential development milestone charges.

The company anticipates 2023 revenue between $30.3 billion and $30.8 billion, driven by volume increases from key growth products. This growth is expected to be partially offset by lower revenue for Alimta® due to its loss of patent exclusivity, no anticipated COVID-19 antibody revenue, and the continued negative impact of foreign exchange rates.

Gross margin as a percent of revenue for 2023 is expected to be approximately 77% on a reported basis and approximately 79% on a non-GAAP basis.

Marketing, selling and administrative expenses for 2023 are expected to be in the range of $6.9 billion to $7.1 billion. Research and development expenses are expected to be in the range of $8.2 billion to $8.4 billion.

Consistent with 2022, the company is not including any potential or pending acquired in-process research and development (IPR&D) and development milestone charges in its initial 2023 guidance and expects to update EPS guidance each quarter as acquired IPR&D and development milestone charges are incurred.

Other income (expense) is expected to be expense in the range of $100 million to $200 million on both a reported and non-GAAP basis.


 4





The 2023 effective tax rate is expected to be approximately 16% on both a reported basis and non-GAAP basis. This assumes the provision in the 2017 Tax Act that requires capitalization and amortization of research and development expenses for tax purposes is deferred or repealed by U.S. Congress this year, effective for the full year 2022 as well as 2023. The tax rate increase also includes the impact from recently enacted Puerto Rico legislation that will become effective starting in 2023, as well as the impact from an expected increase in the proportion of earnings in higher tax jurisdictions.

The following table summarizes the company's 2023 financial guidance:
2023 Guidance
Revenue$30.3 to $30.8 billion
Gross Margin % of Revenue (reported)Approx. 77%
Gross Margin % of Revenue (non-GAAP)Approx. 79%
Marketing, Selling & Administrative$6.9 to $7.1 billion
Research & Development$8.2 to $8.4 billion
Other Income/(Expense)$(200) million to $(100) million
Tax RateApprox. 16%
Earnings per Share (reported)$7.65 to $7.85
Earnings per Share (non-GAAP)$8.10 to $8.30
Non-GAAP guidance reflects adjustments presented in the earnings per share table above.



 5





Webcast of Conference Call
As previously announced, investors and the general public can access a live webcast of the 2023 financial guidance conference call through a link on Lilly's website at investor.lilly.com/webcasts-and-presentations. The conference call will begin at 9 a.m. Eastern time today and will be available for replay via the website.

Non-GAAP Financial Measures
The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (“GAAP”), and this press release and related materials includes a description of certain non-GAAP items that may affect the company’s financial expectations for 2022 and 2023. The company’s non-GAAP financial measures adjust reported results to exclude amortization of intangibles and items that are typically highly variable, difficult to predict, and/or of a size that could have a substantial impact on the company’s reported operations for a period. The company believes that these non-GAAP financial measures provide useful information to investors in evaluating the company’s performance. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP financial measures internally to evaluate the performance of the company’s business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP financial measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.

About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s

 6





disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom. F-LLY

Cautionary Statement Regarding Forward-Looking Statements
This press release contains management's current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "estimate", "project", "intend", "expect", "believe", "target", "anticipate", "forecast" and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated, including the impact of the evolving COVID-19 pandemic or any future pandemic, epidemic, or similar public health threat and the global response thereto; uncertainties related to the company's efforts to develop, manufacture, and distribute potential treatments for COVID-19; the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; the impact and outcome of acquisitions and business development transactions and related integration costs; the expiration of intellectual property protection for certain of the company's products and competition from generic and/or biosimilar products; the company's ability to protect and enforce patents and other intellectual property; changes in patent law or regulations related to data package exclusivity; competitive developments affecting current products and the company's pipeline; market uptake of recently launched products; information technology system inadequacies, breaches, or operating failures; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's information technology systems, networks, and facilities, or those of third parties with whom the company shares its data; unexpected safety or efficacy concerns associated with the company's products; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as the company is largely self-insured; issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of demand, labor shortages, third-party performance, or regulatory actions related to our facilities; reliance on third-party relationships and outsourcing arrangements; regulatory changes or other developments; regulatory actions regarding currently marketed products; continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; devaluations in foreign currency exchange rates or changes in interest rates, and inflation; changes in tax law, tax rates, or events that differ from the company's assumptions related to tax positions; asset impairments and restructuring charges; the impact of global macroeconomic conditions, trade disruptions, global disputes, unrest, war, or other costs, uncertainties and risks related to engaging in business in foreign jurisdictions; changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and regulatory compliance problems or government investigations. In addition, the company may not be able to reliably predict the impact of specified items in its 2023 guidance beyond the next 12 months, and the variability of factors discussed in these forward-looking statements could have a significant and unpredictable impact on the company’s future GAAP results. For additional information about the factors that could cause actual results or events to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release.

 7






    #    #    #



            
Alimta® (pemetrexed disodium, Lilly)
Mounjaro® (tirzepatide injection, Lilly)




Third party trademarks used herein are trademarks of their respective owners.

        

 8

 EX-101.SCH 3 lly-20221213.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 lly-20221213_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 lly-20221213_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Postal Zip Code Entity Address, Postal Zip Code 1.125% Notes due 2051 1.125% Notes due 2051 [Member] 1.125% Notes due 2051 1.625% Notes due 2043 1.625% Notes due 2043 [Member] 1.625% Notes due 2043 1.625% Notes due 2026 1.625% Notes Due June 2, 2026 [Member] 1.625% Notes Due June 2, 2026 [Member] 1.700% Notes due 2049 1.700% Notes due 2049 [Member] 1.700% Notes due 2049 [Member] 1.375% Notes due 2061 1.375% Notes due 2061 [Member] 1.375% Notes due 2061 Document Period End Date Document Period End Date 6.77% Notes due 2036 6.77% Notes Due January 1, 2036 [Member] 6.77% Notes Due January 1, 2036 [Member] Entity Central Index Key Entity Central Index Key 7 1/8% Notes due 2025 7 1/8% Notes Due June 1, 2025 [Member] 7 1/8% Notes Due June 1, 2025 [Member] 2.125% Notes due 2030 2.125% Notes Due June 3, 2030 [Member] 2.125% Notes Due June 3, 2030 [Member] Document Information [Table] Document Information [Table] Entity Emerging Growth Company Entity Emerging Growth Company Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security .500% Notes due 2033 .500% Notes due 2033 [Member] .500% Notes due 2033 Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Written Communications Written Communications Local Phone Number Local Phone Number Soliciting Material Soliciting Material Entity Address, State or Province Entity Address, State or Province City Area Code City Area Code Document Type Document Type Document Information [Line Items] Document Information [Line Items] Class of Stock [Domain] Class of Stock [Domain] Entity Incorporation, Date of Incorporation Entity Incorporation, Date of Incorporation Common Stock (no par value) Common Class A [Member] Cover [Abstract] Cover [Abstract] Entity Address, City or Town Entity Address, City or Town Class of Stock [Axis] Class of Stock [Axis] Pre-commencement Tender Offer Pre-commencement Tender Offer Entity File Number Entity File Number 0.625% Notes due 2031 .625% Notes due 2031 [Member] .625% Notes due 2031 [Member] Amendment Flag Amendment Flag Trading Symbol Trading Symbol Entity Tax Identification Number Entity Tax Identification Number EX-101.PRE 6 lly-20221213_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 logoa31a.jpg begin 644 logoa31a.jpg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htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page
Dec. 13, 2022
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Dec. 13, 2022
Entity Incorporation, State or Country Code IN
Entity File Number 001-06351
Entity Tax Identification Number 35-0470950
Entity Address, Address Line One Lilly Corporate Center
Entity Address, City or Town Indianapolis,
Entity Address, State or Province IN
Entity Address, Postal Zip Code 46285
City Area Code 317
Local Phone Number 276-2000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Registrant Name ELI LILLY AND COMPANY
Entity Central Index Key 0000059478
Amendment Flag false
Entity Emerging Growth Company false
Common Stock (no par value)  
Document Information [Line Items]  
Title of 12(b) Security Common Stock (no par value)
Trading Symbol LLY
Security Exchange Name NYSE
7 1/8% Notes due 2025  
Document Information [Line Items]  
Title of 12(b) Security 7 1/8% Notes due 2025
Trading Symbol LLY25
Security Exchange Name NYSE
1.625% Notes due 2026  
Document Information [Line Items]  
Title of 12(b) Security 1.625% Notes due 2026
Trading Symbol LLY26
Security Exchange Name NYSE
2.125% Notes due 2030  
Document Information [Line Items]  
Title of 12(b) Security 2.125% Notes due 2030
Trading Symbol LLY30
Security Exchange Name NYSE
0.625% Notes due 2031  
Document Information [Line Items]  
Title of 12(b) Security 0.625% Notes due 2031
Trading Symbol LLY31
Security Exchange Name NYSE
6.77% Notes due 2036  
Document Information [Line Items]  
Title of 12(b) Security 6.77% Notes due 2036
Trading Symbol LLY36
Security Exchange Name NYSE
1.700% Notes due 2049  
Document Information [Line Items]  
Title of 12(b) Security 1.700% Notes due 2049
Trading Symbol LLY49A
Security Exchange Name NYSE
.500% Notes due 2033  
Document Information [Line Items]  
Title of 12(b) Security 0.500% Notes due 2033
Trading Symbol LLY33
Security Exchange Name NYSE
1.625% Notes due 2043  
Document Information [Line Items]  
Title of 12(b) Security 1.625% Notes due 2043
Trading Symbol LLY43
Security Exchange Name NYSE
1.125% Notes due 2051  
Document Information [Line Items]  
Title of 12(b) Security 1.125% Notes due 2051
Trading Symbol LLY51
Security Exchange Name NYSE
1.375% Notes due 2061  
Document Information [Line Items]  
Title of 12(b) Security 1.375% Notes due 2061
Trading Symbol LLY61
Security Exchange Name NYSE
XML 9 lly-20221213_htm.xml IDEA: XBRL DOCUMENT 0000059478 2022-12-13 2022-12-13 0000059478 us-gaap:CommonClassAMember 2022-12-13 2022-12-13 0000059478 lly:A718NotesDueJune12025Member 2022-12-13 2022-12-13 0000059478 lly:A1.625NotesDueJune22026Member 2022-12-13 2022-12-13 0000059478 lly:A2.125NotesDueJune32030Member 2022-12-13 2022-12-13 0000059478 lly:A625Notesdue2031Member 2022-12-13 2022-12-13 0000059478 lly:A500NotesDue2033Member 2022-12-13 2022-12-13 0000059478 lly:A6.77NotesDueJanuary12036Member 2022-12-13 2022-12-13 0000059478 lly:A1625NotesDue2043Member 2022-12-13 2022-12-13 0000059478 lly:A1.700Notesdue2049Member 2022-12-13 2022-12-13 0000059478 lly:A1125NotesDue2051Member 2022-12-13 2022-12-13 0000059478 lly:A1375NotesDue2061Member 2022-12-13 2022-12-13 0000059478 false 8-K 2022-12-13 ELI LILLY AND COMPANY IN 001-06351 35-0470950 Lilly Corporate Center Indianapolis, IN 46285 317 276-2000 false false false false Common Stock (no par value) LLY NYSE 7 1/8% Notes due 2025 LLY25 NYSE 1.625% Notes due 2026 LLY26 NYSE 2.125% Notes due 2030 LLY30 NYSE 0.625% Notes due 2031 LLY31 NYSE 0.500% Notes due 2033 LLY33 NYSE 6.77% Notes due 2036 LLY36 NYSE 1.625% Notes due 2043 LLY43 NYSE 1.700% Notes due 2049 LLY49A NYSE 1.125% Notes due 2051 LLY51 NYSE 1.375% Notes due 2061 LLY61 NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 12 22 1 false 11 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.lilly.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports lly-20221213.htm lly-20221213.xsd lly-20221213_def.xml lly-20221213_lab.xml lly-20221213_pre.xml lly-2023financialguidancep.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lly-20221213.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 12, "dts": { "definitionLink": { "local": [ "lly-20221213_def.xml" ] }, "inline": { "local": [ "lly-20221213.htm" ] }, "labelLink": { "local": [ "lly-20221213_lab.xml" ] }, "presentationLink": { "local": [ "lly-20221213_pre.xml" ] }, "schema": { "local": [ "lly-20221213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 39, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 10, "memberStandard": 1, "nsprefix": "lly", "nsuri": "http://www.lilly.com/20221213", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lly-20221213.htm", "contextRef": "i8fb69bfa78ff4dda833c5a0c80ab3656_D20221213-20221213", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://www.lilly.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lly-20221213.htm", "contextRef": "i8fb69bfa78ff4dda833c5a0c80ab3656_D20221213-20221213", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 11, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation, Date of Incorporation", "terseLabel": "Entity Incorporation, Date of Incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "lly_A1.625NotesDueJune22026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.625% Notes Due June 2, 2026 [Member]", "label": "1.625% Notes Due June 2, 2026 [Member]", "terseLabel": "1.625% Notes due 2026" } } }, "localname": "A1.625NotesDueJune22026Member", "nsuri": "http://www.lilly.com/20221213", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A1.700Notesdue2049Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.700% Notes due 2049 [Member]", "label": "1.700% Notes due 2049 [Member]", "terseLabel": "1.700% Notes due 2049" } } }, "localname": "A1.700Notesdue2049Member", "nsuri": "http://www.lilly.com/20221213", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A1125NotesDue2051Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.125% Notes due 2051", "label": "1.125% Notes due 2051 [Member]", "terseLabel": "1.125% Notes due 2051" } } }, "localname": "A1125NotesDue2051Member", "nsuri": "http://www.lilly.com/20221213", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A1375NotesDue2061Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.375% Notes due 2061", "label": "1.375% Notes due 2061 [Member]", "terseLabel": "1.375% Notes due 2061" } } }, "localname": "A1375NotesDue2061Member", "nsuri": "http://www.lilly.com/20221213", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A1625NotesDue2043Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.625% Notes due 2043", "label": "1.625% Notes due 2043 [Member]", "terseLabel": "1.625% Notes due 2043" } } }, "localname": "A1625NotesDue2043Member", "nsuri": "http://www.lilly.com/20221213", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A2.125NotesDueJune32030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.125% Notes Due June 3, 2030 [Member]", "label": "2.125% Notes Due June 3, 2030 [Member]", "terseLabel": "2.125% Notes due 2030" } } }, "localname": "A2.125NotesDueJune32030Member", "nsuri": "http://www.lilly.com/20221213", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A500NotesDue2033Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": ".500% Notes due 2033", "label": ".500% Notes due 2033 [Member]", "terseLabel": ".500% Notes due 2033" } } }, "localname": "A500NotesDue2033Member", "nsuri": "http://www.lilly.com/20221213", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A6.77NotesDueJanuary12036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]", "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]", "terseLabel": "6.77% Notes due 2036" } } }, "localname": "A6.77NotesDueJanuary12036Member", "nsuri": "http://www.lilly.com/20221213", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A625Notesdue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": ".625% Notes due 2031 [Member]", "label": ".625% Notes due 2031 [Member]", "terseLabel": "0.625% Notes due 2031" } } }, "localname": "A625Notesdue2031Member", "nsuri": "http://www.lilly.com/20221213", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "lly_A718NotesDueJune12025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]", "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]", "terseLabel": "7 1/8% Notes due 2025" } } }, "localname": "A718NotesDueJune12025Member", "nsuri": "http://www.lilly.com/20221213", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Common Stock (no par value)" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.lilly.com/role/CoverPage" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0000059478-22-000277-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000059478-22-000277-xbrl.zip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